Terms: = Ovarian cancer AND SDHB, PGL4, 6390, ENSG00000117118, SDH1, SDHIP, SDH, IP AND Diagnosis
38 results:
1. Preclinical Activity of Two Paclitaxel Nanoparticle Formulations After Intraperitoneal Administration in ovarian cancer Murine Xenografts.
Demuytere J; Carlier C; Van de Sande L; Hoorens A; De Clercq K; Giordano S; Morosi L; Matteo C; Zucchetti M; Davoli E; Van Dorpe J; Vervaet C; Ceelen W
Int J Nanomedicine; 2024; 19():429-440. PubMed ID: 38260242
[TBL] [Abstract] [Full Text] [Related]
2. Hypoxia-associated genetic signature in ovarian steroid cell tumor NOS.
Chao A; Huang HJ; Lin CY; Lee CH; Lin CH; Chao AS; Lai CH; Chang TC; Wu KY; Wu RC
Endocr Relat Cancer; 2023 Nov; 30(11):. PubMed ID: 37655726
[TBL] [Abstract] [Full Text] [Related]
3. What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer.
Pitiyarachchi O; Friedlander M; Java JJ; Chan JK; Armstrong DK; Markman M; Herzog TJ; Monk BJ; Backes F; Secord AA; Bonebrake A; Rose PG; Tewari KS; Lentz SS; Geller MA; Copeland LJ; Mannel RS
Gynecol Oncol; 2022 Sep; 166(3):410-416. PubMed ID: 35835612
[TBL] [Abstract] [Full Text] [Related]
4. [A Long Term Survival Case of Gastric cancer with Peritoneal Dissemination Responding to Intraperitoneal Chemotherapy].
Naruse T; Hirono Y; Kurebayashi H; Katayama H; Sawai K; Morikawa M; Koneri K; Tamaki M; Murakami M; Goi T
Gan To Kagaku Ryoho; 2020 Aug; 47(8):1254-1257. PubMed ID: 32829367
[TBL] [Abstract] [Full Text] [Related]
5. The interaction of Lin28A/Rho associated coiled-coil containing protein kinase2 accelerates the malignancy of ovarian cancer.
Zhong Y; Yang S; Wang W; Wei P; He S; Ma H; Yang J; Wang Q; Cao L; Xiong W; Zhou M; Li G; Shuai C; Peng S
Oncogene; 2019 Feb; 38(9):1381-1397. PubMed ID: 30266988
[TBL] [Abstract] [Full Text] [Related]
6. Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.
Grabosch S; Tseng G; Edwards RP; Lankes HA; Moore K; Odunsi K; Vlad A; Ma T; Strange M; Brozick J; Lugade A; Omilian A; Bshara W; Stuckey AR; Walker JL; Birrer M
Gynecol Oncol; 2017 Jul; 146(1):137-145. PubMed ID: 28483269
[TBL] [Abstract] [Full Text] [Related]
7. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
Sioulas VD; Schiavone MB; Kadouri D; Zivanovic O; Roche KL; O'Cearbhaill R; Abu-Rustum NR; Levine DA; Sonoda Y; Gardner GJ; Leitao MM; Chi DS
Gynecol Oncol; 2017 Apr; 145(1):15-20. PubMed ID: 28238354
[TBL] [Abstract] [Full Text] [Related]
8. Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.
Hernandez L; Kim MK; Lyle LT; Bunch KP; House CD; Ning F; Noonan AM; Annunziata CM
Gynecol Oncol; 2016 Aug; 142(2):332-40. PubMed ID: 27235858
[TBL] [Abstract] [Full Text] [Related]
9. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.
Jaaback K; Johnson N; Lawrie TA
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD005340. PubMed ID: 26755441
[TBL] [Abstract] [Full Text] [Related]
10. PMS2 expression in epithelial ovarian cancer is posttranslationally regulated by Akt and essential for platinum-induced apoptosis.
Jia J; Wang Z; Cai J; Zhang Y
Tumour Biol; 2016 Mar; 37(3):3059-69. PubMed ID: 26423401
[TBL] [Abstract] [Full Text] [Related]
11. Intraperitoneal chemotherapy among women in the Medicare population with epithelial ovarian cancer.
Fairfield KM; Murray K; LaChance JA; Wierman HR; Earle CC; Trimble EL; Warren JL
Gynecol Oncol; 2014 Sep; 134(3):473-7. PubMed ID: 24952367
[TBL] [Abstract] [Full Text] [Related]
12. Avidity of onconeural antibodies is of clinical relevance.
Totland C; Ying M; Haugen M; Mazengia K; Storstein A; Aarseth J; Martinez A; Vedeler C
Cancer Immunol Immunother; 2013 Aug; 62(8):1393-6. PubMed ID: 23733227
[TBL] [Abstract] [Full Text] [Related]
13. Effect of perfusion temperature on glucose and electrolyte transport during hyperthermic intraperitoneal chemoperfusion (HIPEC) with oxaliplatin.
Ceelen W; De Somer F; Van Nieuwenhove Y; Vande Putte D; Pattyn P
Eur J Surg Oncol; 2013 Jul; 39(7):754-9. PubMed ID: 22878060
[TBL] [Abstract] [Full Text] [Related]
14. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
[TBL] [Abstract] [Full Text] [Related]
15. Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer.
Meredith R; You Z; Alvarez R; Partridge E; Grizzle W; LoBuglio A
Cancer Biother Radiopharm; 2012 Feb; 27(1):36-40. PubMed ID: 22239432
[TBL] [Abstract] [Full Text] [Related]
16. Extraperitoneal metastases from recurrent ovarian cancer.
Robinson WR; Beyer J; Griffin S; Kanjanavaikoon P
Int J Gynecol Cancer; 2012 Jan; 22(1):43-6. PubMed ID: 22193642
[TBL] [Abstract] [Full Text] [Related]
17. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.
Jaaback K; Johnson N; Lawrie TA
Cochrane Database Syst Rev; 2011 Nov; (11):CD005340. PubMed ID: 22071822
[TBL] [Abstract] [Full Text] [Related]
18. Intraperitoneal chemotherapy for advanced ovarian and peritoneal cancers in patients following interval debulking surgery or primary cytoreductive surgery: Tom Baker cancer Centre experience from 2006 to 2009.
Nelson G; Lucero CA; Chu P; Nation J; Ghatage P
J Obstet Gynaecol Can; 2010 Mar; 32(3):263-9. PubMed ID: 20500971
[TBL] [Abstract] [Full Text] [Related]
19. Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience.
Markman M; Brady M; Hutson A; Berek JS
Int J Gynecol Cancer; 2009 Feb; 19(2):223-9. PubMed ID: 19395997
[TBL] [Abstract] [Full Text] [Related]
20. [A case of PEP(BEP)-resistant ovarian dysgerminoma successfully treated by VeIP therapy].
Ishibashi M; Nakayama K; Oride A; Yeasmin S; Katagiri A; Iida K; Nakayama N; Miyazaki K
Gan To Kagaku Ryoho; 2009 Mar; 36(3):513-7. PubMed ID: 19295284
[TBL] [Abstract] [Full Text] [Related]
[Next]
